A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer
- 1 April 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 167 (4) , 1670-1674
- https://doi.org/10.1016/s0022-5347(05)65175-0
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- HORMONE-REFRACTORY PROSTATE CANCER CELLS EXPRESS FUNCTIONAL FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR)Journal of Urology, 1999
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.Proceedings of the National Academy of Sciences, 1984